You can buy or sell VYGR and other stocks, options, ETFs, and crypto commission-free!
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. Read More The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Stock Price, News, & Analysis for Voyager Therapeutics
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program, for tauopath...
Yahoo FinanceFeb 25
AbbVie Extends Deal With Voyager to Make Parkinson's Drugs
AbbVie (ABBV) expands its collaboration with Voyager Therapeutics to develop potential vectorized antibodies for Parkinson's disease (PD) and other synucleinopathies.
Voyager Therapeutics stock soars after AbbVie collaboration potentially valued at over $1 billion
Shares of Voyager Therapeutics Inc. VYGR, -1.93% ran up 14.2% in premarket trade Friday, after the gene therapy company and AbbVie Inc. ABBV, -1.55% announced a collaboration to develop antibodies to treat Parkinson's disease. AbbVie's stock was still inactive ahead of the open. Under terms of the collaboration, Voyager will receive $65 million upfront and up to $245 million in preclinical and phase 1 option payments, as well as up to an additional $728 million in potential milestone payments and royalties....
Expected May 9, After Hours